Details of the Drug
General Information of Drug (ID: DMJ2PG1)
| Drug Name |
VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL525571; alpha-Cgrp (8-37); Val(8)-phe(37)-cgrp; CGRP8-37; CGRP-(8-37); Calcitonin gene-related peptide (8-37); h alpha-CGRP8-37; 8-Val-37-phe-calcitonin gene-related peptide; Calcitonin gene-related peptide, val(8)-phe(37)-; Calcitonin gene-related peptide, valyl(8)-phenylalanine(37)-; BDBM50000743; NCGC00167246-01; CALCITONIN GENE RELATED PEPTIDE (8-37); [Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2] hC; alpha-Calcitonin gene-r
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 3125.6 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -9.3 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 104 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 47 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 44 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


